GetTopicDetailResponse(id=6bbc15655cc, topicName=Rozlytrek, introduction=Rozlytrek, content=null, image=null, comments=5, allHits=1154, url=https://h5.medsci.cn/topic?id=15655, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=93466, tagList=[TagDto(tagId=93466, tagName=Rozlytrek)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1573342, encodeId=e0e915e334278, content=<a href='/topic/show?id=6bbc15655cc' target=_blank style='color:#2F92EE;'>#Rozlytrek#</a>, objectTitle=Rozlytrek(entrectinib)治療NTRK基因融合的實(shí)體瘤:已獲歐盟批準(zhǔn), objectType=article, longId=198676, objectId=870a1986e628, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870a1986e628, replyNumber=0, likeNumber=129, createdTime=2020-08-05, rootId=0, userName=lanyan20020091, userId=b70f15850841, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870a1986e628, moduleTitle=Rozlytrek(entrectinib)治療NTRK基因融合的實(shí)體瘤:已獲歐盟批準(zhǔn), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=870a1986e628)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573341, encodeId=b26415e33411d, content=<a href='/topic/show?id=6bbc15655cc' target=_blank style='color:#2F92EE;'>#Rozlytrek#</a>, objectTitle=又一“廣譜”抗癌藥獲批:NICE批準(zhǔn)Rozlytrek治療NTRK基因融合的所有實(shí)體瘤, objectType=article, longId=196520, objectId=4e2c19652009, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e2c19652009, replyNumber=0, likeNumber=104, createdTime=2020-06-27, rootId=0, userName=lanyan20020091, userId=b70f15850841, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e2c19652009, moduleTitle=又一“廣譜”抗癌藥獲批:NICE批準(zhǔn)Rozlytrek治療NTRK基因融合的所有實(shí)體瘤, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=4e2c19652009)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573340, encodeId=56e215e3340b2, content=<a href='/topic/show?id=6bbc15655cc' target=_blank style='color:#2F92EE;'>#Rozlytrek#</a>, objectTitle=NICE支持羅氏的ALK抑制劑Rozlytrek,治療ROS1陽性的非小細(xì)胞肺癌患者, objectType=article, longId=195930, objectId=68ef19593022, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=68ef19593022, replyNumber=0, likeNumber=136, createdTime=2020-06-17, rootId=0, userName=lanyan20020091, userId=b70f15850841, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=68ef19593022, moduleTitle=NICE支持羅氏的ALK抑制劑Rozlytrek,治療ROS1陽性的非小細(xì)胞肺癌患者, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=68ef19593022)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573339, encodeId=2ce315e3339e8, content=<a href='/topic/show?id=6bbc15655cc' target=_blank style='color:#2F92EE;'>#Rozlytrek#</a>, objectTitle=精準(zhǔn)醫(yī)療的突破:FoundationOne CDx癌癥基因組譜可用于Rozlytrek治療ROS1陽性肺癌的伴隨診斷, objectType=article, longId=185334, objectId=f8d0185334ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8d0185334ad, replyNumber=0, likeNumber=83, createdTime=2019-12-29, rootId=0, userName=lanyan20020091, userId=b70f15850841, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8d0185334ad, moduleTitle=精準(zhǔn)醫(yī)療的突破:FoundationOne CDx癌癥基因組譜可用于Rozlytrek治療ROS1陽性肺癌的伴隨診斷, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f8d0185334ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1573338, encodeId=97f615e333835, content=<a href='/topic/show?id=6bbc15655cc' target=_blank style='color:#2F92EE;'>#Rozlytrek#</a>, objectTitle=羅氏的ALK抑制劑Rozlytrek獲得FDA批準(zhǔn)治療NTRK基因融合實(shí)體瘤和ROS1陽性NSCLC, objectType=article, longId=177801, objectId=78401e780141, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78401e780141, replyNumber=0, likeNumber=86, createdTime=2019-08-18, rootId=0, userName=lanyan20020091, userId=b70f15850841, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78401e780141, moduleTitle=羅氏的ALK抑制劑Rozlytrek獲得FDA批準(zhǔn)治療NTRK基因融合實(shí)體瘤和ROS1陽性NSCLC, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=78401e780141)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29